- Title: Subtitle
- 731P Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy
- Creators
- M.R. Mirza - Copenhagen University HospitalC. Mathews - Women & Infants Hospital of Rhode IslandL. Gilbert - McGill University Health CentreL. Bjorge - Haukeland University HospitalK. Ring - University of Virginia Health SystemM.M. Pishchyk - Oncology Surgery, Grodno University Clinic, Grodno, BelarusK. Pennington - University of Washington Medical CenterY. Segev - Technion – Israel Institute of TechnologyM.A. Powell - Washington University in St. LouisT. Van Gorp - Division of Gynaecologic Oncology, University Hospital Leuven, Leuven Cancer Institute, KU Leuven, Belgium and the Belgian and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, BelgiumD. Bender - University of IowaK. Schneider - Novant HealthR. Miller - Markey Cancer CenterA. Armstrong - University Hospitals of ClevelandG. Canturia - Northside HospitalR. Gogoi - Wayne State UniversityG. Antony - Biostatistics, GSK, London, UKS. Stevens - Global Clinical Development. Immuno-Oncology, GSK, London, UKG. Valabrega - University of TurinL.M. Landrum - Indiana University Health
- Resource Type
- Abstract
- Publication Details
- Annals of oncology, Vol.35(Supplement 2), pp.S556-S556
- DOI
- 10.1016/j.annonc.2024.08.793
- ISSN
- 0923-7534
- Publisher
- Elsevier Ltd
- Language
- English
- Date published
- 09/2024
- Academic Unit
- Obstetrics and Gynecology
- Record Identifier
- 9984708761402771
Abstract
731P Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy
Annals of oncology, Vol.35(Supplement 2), pp.S556-S556
09/2024
DOI: 10.1016/j.annonc.2024.08.793
Details
Metrics
27 Record Views